Since bradycardia is a risk factor for development of TdP, the potential occurrence of bradycardia during octreotide administration could theoretically increase the risk of TdP in patients receiving drugs that prolong the QT interval.
Patients with respiratory depression should be treated cautiously with cyclic antidepressants because of the CNS depressant effects of this class of drugs.
If you plan to get pregnant, talk to your doctor about other ways to lower your blood pressure.
Little is known about the pharmacokinetics in pregnant women.
Side effects, drug interactions, dosage, storage, and pregnancy safety information should be reviewed prior to taking this medication.